Data suggest smoking doesn't impact RA treatment response

December 21, 2012
Data suggest smoking doesn't impact RA treatment response
For patients with early rheumatoid arthritis, smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according to a study published in the December issue of Arthritis Care & Research.

(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according to a study published in the December issue of Arthritis Care & Research.

Leann B. Maska, M.D., from the University of Nebraska Medical Center in Omaha, and colleagues analyzed data from 412 patients with early RA (less than three years in duration) enrolled in the Treatment of Early Aggressive study, a randomized, blinded, placebo-controlled clinical trial comparing early intensive therapy ( + etanercept or methotrexate + hydroxychloroquine + sulfasalazine triple therapy) with initial methotrexate treatment with step-up to methotrexate + etanercept or to triple therapy if the disease was still active at 24 weeks. At baseline and at 48 weeks, serum cotinine was measured as an indicator for smoking status, and the mean Disease Activity Score in 28 joints (DAS28) was compared by smoking status.

The researchers found that 71 percent of participants were categorized as nonsmokers and 29 percent as current smokers. Based on smoking status, there were no differences noted in the mean DAS28 between 48 and 102 weeks for the group (P = 0.881), or by specific treatment allocation.

"Among RA patients who smoke, effective cessation strategies remain essential for general health considerations," the authors write. "However, our data would suggest smoking cessation alone may not be an important adjunct in lessening disease activity or modifying therapeutic response to commonly used disease-remitting treatments in RA."

Two authors disclosed financial ties to pharmaceutical companies, including Amgen, which funded the study. Amgen, Barr Pharmaceuticals, and Pharmacia provided the study drugs.

Explore further: Gender, high DAS28-P index predictive of pain in early RA

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Gender, high DAS28-P index predictive of pain in early RA

May 18, 2012

(HealthDay) -- For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness and visual analog score) ...

Methotrexate use linked to reduced mortality in RA

October 14, 2012

(HealthDay)—Use of methotrexate for one year or more is associated with a reduction in the risk of mortality for patients with rheumatoid arthritis (RA), according to a study published online Oct. 8 in Arthritis & Rheumatism.

Recommended for you

Low vitamin D tied to dry eye syndromes

August 23, 2015

(HealthDay)—Patients with vitamin D deficiency should be evaluated for dry eye syndromes, according to a study published online Aug. 13 in the International Journal of Rheumatic Diseases.

Yoga improves arthritis symptoms and mood, study finds

September 15, 2015

A randomized trial of people with two common forms of arthritis has found that yoga can be safe and effective for people with arthritis. Johns Hopkins researchers report that 8 weeks of yoga classes improved the physical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.